Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...
Emcure Pharma becomes the first Indian company to hold exclusive rights to distribute and commercialise Poviztra, a ...
Novo Nordisk India partners with Emcure Pharma to distribute and market Poviztra (semaglutide) nationwide, expanding access ...
23h
The next-generation weight loss drug that’s ‘as effective as Mounjaro – WITHOUT Ozempic side effect’
A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...
Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...
Danish drugmaker Novo Nordisk has partnered Emcure Pharmaceuticals to commercialise Poviztra, a 2.4 milligram (mg) ...
Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases (AASLD), ...
Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...
Asianet Newsable on MSN
Novo Nordisk, Emcure to launch weight loss drug Poviztra in India
Novo Nordisk India and Emcure Pharma have partnered to launch Poviztra (semaglutide 2.4 mg), a second brand of Wegovy®, in ...
Novo Nordisk India and Emcure Pharma announced a strategic partnership on Monday to launch Poviztra (semaglutide injection 2.4 mg) in India. The collaboration aims to enhance the distribution and ...
Weight loss refers to a reduction in overall body weight, while fat loss specifically targets excess body fat, improving body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback